Market LIVE
Published markets; coverage varies by country
Product profile · United States

PICATO

 ·  Patent Litigation & Settlement History ↓

IngredientINGENOL MEBUTATE
Application typeNDA
Application202833
Product001
Dosage formGEL
RouteTOPICAL
Strength0.015%
Approval date2012-01-23
Marketing statusDiscontinued
Status event—
ApplicantLEO LABS
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2019-01-07
Status event—

Final ANDA candidate 209018/001 on 2019-01-07. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
83728272026-12-18DP ————
———
83728282026-12-18DP ————
———
83779192026-12-18DP ————
———
85361632026-12-18U U-1440———
———
87162712026-12-18U U-1440———
———
87353752026-12-18U U-1440———
———
98209592026-12-18DP/U U-1440———
———
98334282026-12-18DP ————
———
98334292026-12-18DP ————
———
98616032026-12-18U U-1440———
———
82782922027-07-06DP ————
———
97890782033-05-15U U-2138———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
209018 / 001FINAL_APPROVAL · FINAL_APPROVED2019-01-07—PADAGIS ISRAEL PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
209018 / 001PADAGIS ISRAEL PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2019-01-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.